UBS analyst AJ Rice lowered the firm’s price target on Acadia Healthcare (ACHC) to $24 from $28 and keeps a Buy rating on the shares. Acadia lowered its 2025 guidance due to a $50M liability reserve accrual expected in Q4, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Leerink downgrades Acadia Healthcare on ‘real risk’ of legal liabilities
- Acadia Healthcare price target lowered to $25 from $30 at KeyBanc
- BofA downgrades Acadia Healthcare to Underperform after another guidance cut
- Acadia Healthcare downgraded to Underperform from Neutral at BofA
- Acadia Healthcare downgraded to Market Perform from Outperform at Leerink